<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02171884</url>
  </required_header>
  <id_info>
    <org_study_id>FAUQUE DB 2013</org_study_id>
    <nct_id>NCT02171884</nct_id>
  </id_info>
  <brief_title>Study of the Impact of Freezing-thawing Procedures and the Prolonged Culture of Embryos on Epigenetic Regulation in Humans</brief_title>
  <official_title>Study of the Impact of Freezing-thawing Procedures and the Prolonged Culture of Embryos on Epigenetic Regulation in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <brief_summary>
    <textblock>
      For this project, 4 groups of 38 infants have been created so as to evaluate the impact of
      Assisted-Reproduction Technology (ART) and more particularly the two procedures classically
      used in ART: the freezing/thawing of embryos and prolonged embryo culture (five days of
      culture in appropriate in vitro conditions to allow development of the embryo) in contrast
      with shorter culture of only two days.

      Participation consists in accepting samples to be taken at the birth of the infant:

        1. from the umbilical cord.

        2. from the placenta.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 17, 2013</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Analysis of the expression of several genes subjected to imprinting (H19, IGF2, IGF2R, MEST, PEG3, SNRPN, IGF2, KCNQ1, GRB10 and PLAGL1)</measure>
    <time_frame>Baselines</time_frame>
    <description>DNA / RNA extraction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of the expression of 3 transposable elements (HERV-K, LINE-1 and ALU)</measure>
    <time_frame>Baselines</time_frame>
    <description>DNA / RNA extraction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Level of methylation and the level of expression of Genomic Imprinting (GI) and Transposable Elements (TE)</measure>
    <time_frame>Baselines</time_frame>
    <description>DNA / RNA extraction</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">366</enrollment>
  <condition>Assisted Reproductive Technology</condition>
  <condition>Freezing/Thawing Procedure</condition>
  <condition>Prolonged Culture Procedure</condition>
  <arm_group>
    <arm_group_label>Group E1</arm_group_label>
    <description>Singletons born following ART via IVF/ICSI (short culture)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group EC1</arm_group_label>
    <description>Singletons born following ART via IVF/ICSI and freezing-thawing of the embryo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group T1</arm_group_label>
    <description>Singletons conceived naturally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E2</arm_group_label>
    <description>Singletons born following ART with IVF/ICSI (prolonged culture)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sample of cord blood</intervention_name>
    <arm_group_label>Group E1</arm_group_label>
    <arm_group_label>Group E2</arm_group_label>
    <arm_group_label>Group EC1</arm_group_label>
    <arm_group_label>Group T1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sample of placenta</intervention_name>
    <arm_group_label>Group E1</arm_group_label>
    <arm_group_label>Group E2</arm_group_label>
    <arm_group_label>Group EC1</arm_group_label>
    <arm_group_label>Group T1</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        4 groups of infants:

          -  conceived naturally

          -  born following ART with IVF/ICSI (short culture)

          -  born following ART with IVF/ICSI and freezing/thawing of the embryo

          -  born following ART with IVF/ICSI (prolonged culture)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who have provided written informed consent,

          -  Patients with national health insurance cover,

          -  Maternal age at conception between 20 and 43 years,

          -  Paternal age at conception between 18 and 50 years,

          -  Singleton pregnancy

        Exclusion Criteria:

        ---Maternal disease:

          -  pulmonary, cardiac

          -  renal and metabolic diseases (including type 1 and 2 diabetes prior to the pregnancy)

          -  systemic inflammatory diseases

          -  hypertension

          -  neurological diseases

          -  chronic hepatitis B or C

          -  HIV infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Patricia FAUQUE</last_name>
    <phone>3 80 29 35 64</phone>
    <phone_ext>+33</phone_ext>
    <email>patricia.fauque@chu-dijon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de BESANCON</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Didier RIETHMULLER</last_name>
      <phone>3 81 66 91 11</phone>
      <phone_ext>+33</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de DIJON</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia FAUQUE</last_name>
      <phone>3 80 29 35 64</phone>
      <phone_ext>+33</phone_ext>
      <email>patricia.fauque@chu-dijon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>June 18, 2014</study_first_submitted>
  <study_first_submitted_qc>June 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2014</study_first_posted>
  <last_update_submitted>August 14, 2019</last_update_submitted>
  <last_update_submitted_qc>August 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

